These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18533605)

  • 41. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.
    Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994
    [No Abstract]   [Full Text] [Related]  

  • 42. Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
    Green JB; Feinglos MN
    Curr Diab Rep; 2007 Oct; 7(5):369-75. PubMed ID: 18173970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C; Bollaerts K
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes.
    Guliani A; Bishnoi A; Aggarwal D; Parsad D
    Postgrad Med J; 2018 Nov; 94(1117):662-663. PubMed ID: 30317183
    [No Abstract]   [Full Text] [Related]  

  • 46. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
    Gallwitz B
    MMW Fortschr Med; 2014 Jul; 156(13):57-60. PubMed ID: 25318228
    [No Abstract]   [Full Text] [Related]  

  • 47. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
    Freeman JS
    J Am Osteopath Assoc; 2010 Sep; 110(9):528-37. PubMed ID: 20876838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].
    Roussel R
    Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():33-5. PubMed ID: 17961659
    [No Abstract]   [Full Text] [Related]  

  • 50. Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
    Nathan DM
    Ann Intern Med; 2011 Jan; 154(2):131-2. PubMed ID: 21135287
    [No Abstract]   [Full Text] [Related]  

  • 51. Saxagliptin, alogliptin, and cardiovascular outcomes.
    White WB; Zannad F
    N Engl J Med; 2014 Jan; 370(5):484. PubMed ID: 24482824
    [No Abstract]   [Full Text] [Related]  

  • 52. Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases.
    Nagai H; Fujiwara S; Takahashi Y; Nishigori C
    J Dermatol; 2015 Nov; 42(11):1094-7. PubMed ID: 26031638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Editorial: Newer peptide-based agents for treatment of patients with Type 2 diabetes.
    Flatt PR; Conlon JM
    Peptides; 2018 Feb; 100():1-2. PubMed ID: 29412809
    [No Abstract]   [Full Text] [Related]  

  • 54. Acute pancreatitis with dipeptidyl peptidase-4 (DPP4) inhibitor or fulminant type 1 diabetes?
    Amouyal C; Levy P; Andreelli F; Hartemann A
    Diabetes Metab; 2018 Feb; 44(1):95-96. PubMed ID: 28483292
    [No Abstract]   [Full Text] [Related]  

  • 55. Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
    Scheen AJ; Van Gaal LF
    Eur Heart J; 2007 Jun; 28(11):1401-2; author reply 1402. PubMed ID: 17493946
    [No Abstract]   [Full Text] [Related]  

  • 56. No increased heart failure risk is reported with DPP-4 inhibitors.
    Wise J
    BMJ; 2016 Apr; 353():i2363. PubMed ID: 27118534
    [No Abstract]   [Full Text] [Related]  

  • 57. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
    Golay A
    Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
    [No Abstract]   [Full Text] [Related]  

  • 58. Erroneous event count in a meta-analysis (dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus).
    Buisson M; Cornu C; Nony P
    Am J Cardiol; 2015 Mar; 115(6):852. PubMed ID: 25554535
    [No Abstract]   [Full Text] [Related]  

  • 59. Omarigliptin: first global approval.
    Burness CB
    Drugs; 2015 Nov; 75(16):1947-52. PubMed ID: 26507988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials.
    Packer M
    Am J Med; 2018 Jul; 131(7):e287-e289. PubMed ID: 29307538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.